TickerFacts.

Immuneering Corp (IMRX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$59.05M
Year ended 2025-12-31
-$63.15M
Trailing 12 months to 2026-06-30
2023-12-31: -$58.09M2024-12-31: -$63.72M2025-12-31: -$59.05M-$59.05M
2023-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$59.05Mn/m2026-03-06, From 2025-01-01
2024-12-31-$63.72Mn/m2026-03-06, From 2024-01-01
2023-12-31-$58.09Mn/a2025-03-20, From 2023-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Immuneering Corp (IMRX)2025-12-31-$59.05Mn/m
Evolus, Inc. (EOLS)2025-12-31-$25.16Mn/m
Evommune, Inc. (EVMN)2025-12-31-$80.47Mn/m
Lifecore Biomedical, Inc. (LFCR)2025-05-25-$9.22Mn/m
Abeona Therapeutics Inc. (ABEO)2025-12-31-$86.90Mn/m
Siga Technologies Inc (SIGA)2025-12-31$24.26M-65.6%
Puma Biotechnology, Inc. (PBYI)2025-12-31$48.24M+13.5%
Savara Inc (SVRA)2025-12-31-$123.46Mn/m
Heron Therapeutics, Inc. (HRTX)2025-12-31-$224.0Kn/m

Compare IMRX, EOLS, EVMN, LFCR side by side · Screen every company in Pharmaceutical Preparations ↗